Pharmacokinetic Study of Stiripentol and Its Metabolites After Multiple Dose Oral Administration in Healthy Male Volunteers

Healthy Volunteers Clinical Trial

Official title:

Pharmacokinetic Study of Stiripentol and Its Metabolites After Multiple Dose Oral Administration in Healthy Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03866928
• Other study ID #: STP199
• Status: Completed
• Phase: Phase 1
• Start date: February 12, 2019
• Est. completion date: April 5, 2019

Study information

• Verified date: December 2019
• Source: Biocodex
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a monocentric open label study to assess the PK parameters of stiripentol and its metabolites (if any are detected) after multiple oral doses in 14 healthy male subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: April 5, 2019
• Est. primary completion date: April 5, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

Subjects will be required to satisfy the following criteria:

1. Healthy male subject, aged between 18 and 45 years inclusive.

2. Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination).

3. Body mass index (BMI) between 18 and 30 kg/m² inclusive.

4. Normal blood pressure (BP) and heart rate (HR) at the screening visit after 5 min in supine position:

• 90 mmHg = Systolic Blood Pressure (SBP) = 145 mmHg,

• 45 mmHg = Diastolic Blood Pressure (DBP) = 90 mmHg,

• 40 bpm = HR = 90 bpm,

• Or considered not clinically significant (NCS) by the Investigator.

5. Normal electrocardiogram (ECG) recording on a 10 min resting 12-lead ECG at the screening visit:

• 120 = interval between P and R waves (PR) < 210 ms,

• Interval between Q and S waves (QRS) < 120 ms,

• Fridericia corrected interval between Q and T waves (QTcF) = 450 ms,

• No sign of any trouble of sinusal automatism,

• Or considered NCS by the Investigator.

6. Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator.

7. Normal dietary habits.

8. Has given written informed consent.

Exclusion Criteria:

All the subjects included in the study must not meet any of the following non-inclusion criteria.

1. Unsuitable veins for repeated venipuncture.

2. Any relevant history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, infectious disease or psychiatric disorders,

3. Evidence of any clinically significant acute or chronic disease,

4. Surgery or blood donation (including in the frame of a clinical trial) within 2 months before administration,

5. Presence or relevant history of drug hypersensitivity, asthma or allergic disease diagnosed and treated by a physician,

6. Known hypersensitivity to any of the test materials or related compounds,

7. Inability to abstain from intensive muscular effort,

8. Inability or difficulty swallowing whole capsules

9. No possibility of contact in case of emergency,

10. Any drug intake (except paracetamol) including over the counter (OTC) medications and herbal products that could affect the outcome of the study, within 2 weeks prior to the first drug administration or less than 5 times the t1/2 of that drug, whichever is longer,

11. Who receive carbamazepine, phenytoin or phenobarbital known to affect hepatic metabolism within 1 month prior to the first dose administration,

12. Who receive any drug known to interfere with CYP enzymes within 1 month prior to the first dose administration,

13. History or presence of drug or alcohol abuse (alcohol consumption > 4 glasses per day (1 glass is approximately equivalent to: beer [354 mL], wine [118 mL], or distilled spirits [29.5 mL]) per day)),

14. Excessive consumption of beverages with xanthine bases (> 5 cups or glasses / day),

15. Current use of nicotine containing products, i.e., more than 5 cigarettes or equivalent/day or the inability to stop using nicotine containing products during confinement in the clinical center,

16. Intake of any food or any beverage containing grapefruit or grapefruit juice within one week prior to the first dosing and the inability to stop such intake during the study,

17. Positive Hepatitis B surface antigen (HBsAg) or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests,

18. Positive results of screening for drugs of abuse,

19. Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development,

20. Exclusion period of a previous study,

21. Administrative or legal supervision.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Stiripentol
1500 mg of stiripentol b.i.d.

Locations

Country	Name	City	State
Belgium	ATC	Liège

Sponsors (1)

Lead Sponsor	Collaborator
Biocodex

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Plasma Concentration [Cmax]	To determine Cmax of stiripentol and its metabolites (if any are detected) in plasma	On Days 1 and 15
Primary	Area Under the Curve [AUC]	To determine AUC of stiripentol and its metabolites (if any are detected) in plasma	On Days 1 and 15
Primary	Time that a drug is present at the maximum concentration [Tmax]	To determine Tmax of stiripentol and its metabolites (if any are detected) in plasma	On Days 1 and 15
Primary	The minimum concentration [Cmin]	To determine Cmin of stiripentol and its metabolites (if any are detected) in plasma	From Day 2 to Day 15
Primary	Amount of drug excreted in urine [Ae]	To determine Ae of stiripentol and its metabolites (if any are detected) in urine	From Day 2 to Day 15
Primary	Fraction of the dose excreted in urine [fe]	To determine fe of stiripentol and its metabolites (if any are detected) in urine	From Day 2 to Day 15
Secondary	Treatment-related adverse events [TRAEs]	To assess the safety and tolerability of stiripentol and its metabolites (if any are detected) after multiple oral doses of 1500 mg b.i.d in healthy male volunteers	From start of participation of the subject until 4 weeks after the last administration of the study drug